AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

QIAGEN

QGEN's expanded collaboration with AstraZeneca to focus on developing companion diagnostics beyond oncology.

QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases

AstraZeneca (LON: AZN) share price is firing on all cylinders as it sits on its all-time high. It has soared in the last five consecutive weeks, the longest streak since April 2023.

AstraZeneca share price has gone vertical; brace for a pullback

Per third-party reports, AstraZeneca (AZN) has refuted rumors about considering a change in the relocation of a vaccine manufacturing plant from the U.K. to the United States.

AstraZeneca (AZN) Denies Rumors About UK Facility Relocation

British biotech giant AstraZeneca PLC (LSE:AZN) has rebuffed claims that it is moving its vaccine operations to the US. A Financial Times report suggested that AstraZeneca could relocate its vaccine manufacturing operations to Philadelphia due to the Labour government' plans to cut state aid.

Rumours of AstraZeneca relocating vaccine ops to US ‘untrue'

AstraZeneca has warned it could relocate its vaccine manufacturing site from the UK to the U.S. amid a deadlock in negotiations with the Labour government over plans to cut state aid promised to the project, the Financial Times reported on Thursday.

AstraZeneca warns of moving UK vaccine production to US, FT reports

This column is part of the eighth annual Heard on the Street stock picking contest.

AstraZeneca Is a Cancer Leader. Obesity Could Be a Bonus.

GlaxoSmithKline

Johnson & Johnson

Eli Lilly

Merck

Novo Nordisk

Novartis

Pfizer

Roche Holding AG

Sanofi

In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.

Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer.

ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer

This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.

FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer

AstraZeneca PLC's (LSE:AZN) blockbuster immunotherapy cancer drug Imfinzi (durvalumab) has received another approval in the US. In combination with chemotherapy, patients suffering resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) can now receive Imfinzi before and after surgery.

AstraZeneca receives another US approval for cancer drug Imfinzi

The U.S. Food and Drug Administration approved AstraZeneca's blockbuster cancer drug, Imfinzi, for the treatment of patients with a type of non-small cell lung cancer on Thursday.

US FDA approves AstraZeneca's Imfinzi for lung cancer treatment

Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.

Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations

AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.

AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer

AstraZeneca said on Thursday the U.S. Food and Drug Administration (FDA) has granted its cancer drug Imfinzi a priority review for patients with limited-stage small cell lung cancer in the United States.

AstraZeneca's Imfinzi gets FDA priority review for type of lung cancer

Intuitive Surgical

T-Mobile US

In a market characterized by uncertainty and volatility, it's increasingly rare to find stocks that are weathering the storm and thriving. Yet, a select few from various sectors are doing just that—hitting all-time highs even as the broader market indices attempt to regain their footing.

Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs

AstraZeneca PLC (LSE:AZN) will have to scale back plans to expand its Merseyside vaccine manufacturing site after it was revealed the government is set to cut some of the project's funding. Of the £450 million forecast to be spent to facilitate the site development, the former Tory government had promised to contribute £65 million.

AstraZeneca faces state funding blow at Merseyside project

The outlook for pharmaceutical stocks has been mixed in the last five years. During the pandemic, the early-movers in the vaccine race gained as compared to others.

3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct

AstraZeneca PLC (LSE:AZN) has become the first UK-listed company to surpass a £200 billion stock market valuation after shares gained on Tuesday. Shares ticked up 1.2% to 12,928p throughout the day, leaving the pharmaceutical giant with a £200.02 billion valuation.

AstraZeneca first London-listed company to surpass £200bn valuation

Ionis Pharma

AstraZeneca, Ionis and Sanofi are included in this Analyst Blog.

The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi

AstraZeneca's CEO has a vision for the weight loss drugs market. There probably won't be one medicine that's useful in every niche.

Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market

AstraZeneca PLC (LSE:AZN) shares fell more than 1.7% on Tuesday after the English healthcare watchdog said that it could not recommend the drug company's breast cancer drug for the NHS. The National Institute for Health and Care Excellence (Nice) said it was unable to recommend Enhertu for use in NHS England for advanced a common form of breast cancer, HER-2-low breast cancer.

AstraZeneca falls after UK drug watchdog blocks NHS access to Enhertu drug

AbbVie

Amgen

Bristol-Myers

Four pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare program said they do not expect a significant impact on their businesses after seeing confidential suggested prices from the government for their drugs that will take effect in 2026.

Pharma companies less concerned after hearing from US on negotiated prices for Medicare

A new combination treatment has shown significant improvement in treating chronic lymphocytic leukaemia (CLL) in a recent clinical trial. The AMPLIFY Phase III study found that a fixed duration of AstraZeneca PLC's (LSE:AZN) Calquence (acalabrutinib) combined with venetoclax, with or without obinutuzumab, helped patients live longer without the disease getting worse, compared to the current standard chemotherapy.

AstraZeneca shows promise in phase III study

ING Groep NV

Intesa Sanpaolo SpA

T. Rowe Price Group

Nevertheless, its member economies are poised for a rebound.

Europe's Markets Are Cheap. 4 Stocks to Play.

AstraZeneca PLC NASDAQ: AZN is a United Kingdom-based healthcare firm and the sixth-largest pharmaceutical company in the world by market capitalization. So far, in 2024, the firm has outperformed the market and its sector, achieving a total return of 17%.

AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance

News for AstraZeneca Stock (AZN)